The Value of Health Technology Assessment Scientific Advice

Posted 23 August 2017 By Amina Udechuku, PhD, Matthew William Bending, PhD, MSc

placeholder+image In recent years, particularly in Europe, a paradigm shift in the regulatory and Health Technology Assessment (HTA) environment has led to an increase in multi-stakeholder acceptance of integrated scientific advice. This article discusses how using integrated scientific advice can support companies in optimizing their product development programs and generate evidence relevant to regulators, HTA bodies and payers.

Share this article:

Categories: Biologics and biotechnology, Drugs, Features, US, Canada, Europe, FDA, EMA, NICE

Tags: Health Technology Assessment, HTA

Regulatory Exchange: Latest Updates From the Community